De Novo AI‐Designed Peptide‐Functionalized Nanoparticles Modulate Lipid Metabolism to Ameliorate Metabolic Dysfunction–Associated Steatohepatitis
Advanced Functional Materials · 11.11.2026
DOI: 10.1002/adfm.79571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 11.11.2026. Verfasst von Zhiru Yang und 12 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatohepatitis (MASH) is characterized by the excessive accumulation of triglycerides (TG) in the liver, with long‐chain fatty acids (LCFAs) as key TG precursors. CD36, a pivotal transporter, facilitates the uptake of LCFAs into hepatocytes. Currently, there are no effective pharmacological treatments available for early‐stage MASH. To address this, we developed AILITIX, a de novo AI‐designed lipid transport inhibitor. AILITIX exhibits high binding affinity for CD36 and effectively inhibits CD36‐mediated fatty acid uptake. We then synthesized ultrasound‐responsive, liver‐targeted liposomal nanoparticles (NPs) surface‐functionalized with AILITIX and indocyanine green (ICG), and encapsulating the natural flavonoid isoquercitrin (IQ) and the FXR agonist obeticholic acid (OCA). In vitro assays demonstrated that IQ directly binds to and inhibits ACSL4 activity, thereby suppressing SREBF1‐driven de novo lipogenesis. Furthermore, the NPs inhibited the phosphorylation of mTOR, ULK1, and TFEB, activating the autophagy pathway, enhancing lipid degradation, and alleviating oxidative and mitochondrial stress. In murine models, the NPs treatment led to synergistic amelioration of steatosis, oxidative damage, and inflammation. Moreover, single‐cell transcriptomics demonstrated that the intervention suppresses fibrosis‐associated gene expression and reshapes the hepatic immune microenvironment. Collectively, our de novo AI‐designed peptide‐based nanotherapeutics presents a great potential for the precision treatment of MASH.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Yang, Z., Li, X., Lu, S., Zhang, L., Yuan, Y., Han, Y., Gao, X., He, M., Yan, J., Zhu, C., Chen, L., Ding, J., & Kang, J. (2026). De Novo AI‐Designed Peptide‐Functionalized Nanoparticles Modulate Lipid Metabolism to Ameliorate Metabolic Dysfunction–Associated Steatohepatitis. Advanced Functional Materials. https://doi.org/10.1002/adfm.79571
Vancouver
Yang Z, Li X, Lu S, Zhang L, Yuan Y, Han Y, et al. De Novo AI‐Designed Peptide‐Functionalized Nanoparticles Modulate Lipid Metabolism to Ameliorate Metabolic Dysfunction–Associated Steatohepatitis. Advanced Functional Materials. 2026. doi:10.1002/adfm.79571
BibTeX
@article{Yang2026,
author = {Yang, Zhiru and Li, Xiaoke and Lu, Shuai and Zhang, Liang and Yuan, Yuxuan and Han, Yuqi and Gao, Xiaoning and He, Mengxin and Yan, Jun and Zhu, Cheng and Chen, Liqun and Ding, Jianmin and Kang, Jun},
title = {De Novo AI‐Designed Peptide‐Functionalized Nanoparticles Modulate Lipid Metabolism to Ameliorate Metabolic Dysfunction–Associated Steatohepatitis},
journal = {Advanced Functional Materials},
year = {2026},
doi = {10.1002/adfm.79571}
}
EUVIMED